Cutler Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Cutler Group’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,400	Closed	-$2K	–	6534
2021 Q3	$2K	Buy	+3,400	New	+$39.7K	﹤0.01%	5197
2020 Q2	–	Sell	-400	Closed	-$2K	–	5126
2020 Q1	$2K	Buy	+400	New	+$1.51K	﹤0.01%	3608

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Cutler Group's TRIL Position: Q4 2021 in Review

Cutler Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 4,900 shares — an estimated $86K sold.

Cutler Group first reported a position in TRIL in Q1 2020 and held it in 3 quarters. The position peaked at $86K in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Cutler Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 4,900 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $86K.
Cutler Group first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 3 quarters.
Cutler Group's Trillium Therapeutics Inc. position peaked at $86K in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.